These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34199134)

  • 1. Effect of Aprotinin and Avifavir
    Ivashchenko AA; Azarova VN; Egorova AN; Karapetian RN; Kravchenko DV; Krivonos NV; Loginov VG; Poyarkov SV; Merkulova EA; Rosinkova OS; Savchuk NP; Topr MA; Simakina EN; Yakubova EV; Ivachtchenko AV
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34199134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
    Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
    Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.
    Lammers AJJ; Brohet RM; Theunissen REP; Koster C; Rood R; Verhagen DWM; Brinkman K; Hassing RJ; Dofferhoff A; El Moussaoui R; Hermanides G; Ellerbroek J; Bokhizzou N; Visser H; van den Berge M; Bax H; Postma DF; Groeneveld PHP
    Int J Infect Dis; 2020 Dec; 101():283-289. PubMed ID: 33007454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.
    Mallat J; Hamed F; Balkis M; Mohamed MA; Mooty M; Malik A; Nusair A; Bonilla MF
    Medicine (Baltimore); 2020 Dec; 99(52):e23720. PubMed ID: 33350752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
    Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
    J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
    Choi MJ; Kang M; Shin SY; Noh JY; Cheong HJ; Kim WJ; Jung J; Song JY
    Int J Infect Dis; 2021 Jan; 102():275-281. PubMed ID: 33127507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
    Lagier JC; Million M; Gautret P; Colson P; Cortaredona S; Giraud-Gatineau A; Honoré S; Gaubert JY; Fournier PE; Tissot-Dupont H; Chabrière E; Stein A; Deharo JC; Fenollar F; Rolain JM; Obadia Y; Jacquier A; La Scola B; Brouqui P; Drancourt M; Parola P; Raoult D;
    Travel Med Infect Dis; 2020; 36():101791. PubMed ID: 32593867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
    Redondo-Calvo FJ; Padín JF; Muñoz-Rodríguez JR; Serrano-Oviedo L; López-Juárez P; Porras Leal ML; González Gasca FJ; Rodríguez Martínez M; Pérez Serrano R; Sánchez Cadena A; Bejarano-Ramírez N; Muñoz Hornero C; Barberá Farré JR; Domínguez-Quesada I; Sepúlveda Berrocal MA; Villegas Fernández-Infantes MD; Manrique Romo MI; Parra Comino Á; Pérez-Ortiz JM; Gómez-Romero FJ;
    Eur J Clin Invest; 2022 Jun; 52(6):e13776. PubMed ID: 35342931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
    Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z
    Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.
    Wright JK; Tan DHS; Walmsley SL; Hulme J; O'Connor E; Snider C; Cheng I; Chan AK; Borgundvaag B; McLeod S; Gollob MH; Clarke RJ; Dresser L; Haji F; Mazzulli T; Mubareka S; Jüni P; Lee D; Tomlinson G; Kain KC; Landes M
    Trials; 2020 Jul; 21(1):647. PubMed ID: 32665039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients.
    Million M; Lagier JC; Tissot-Dupont H; Ravaux I; Dhiver C; Tomei C; Cassir N; Delorme L; Cortaredona S; Amrane S; Aubry C; Bendamardji K; Berenger C; Doudier B; Edouard S; Hocquart M; Mailhe M; Porcheto C; Seng P; Triquet C; Gentile S; Jouve E; Giraud-Gatineau A; Chaudet H; Camoin-Jau L; Colson P; Gautret P; Fournier PE; Maille B; Deharo JC; Habert P; Gaubert JY; Jacquier A; Honore S; Guillon-Lorvellec K; Obadia Y; Parola P; Brouqui P; Raoult D
    Rev Cardiovasc Med; 2021 Sep; 22(3):1063-1072. PubMed ID: 34565108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.